Get the Stockscreener App
33.40
1.18%
-0.40
After Hours:
33.50
0.10
+0.30%
Vor Biopharma Inc stock is traded at $33.40, with a volume of 436.48K.
It is down -1.18% in the last 24 hours and down -15.66% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$33.80
Open:
$34.12
24h Volume:
436.48K
Relative Volume:
1.20
Market Cap:
$231.66M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-20.37
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-14.93%
1M Performance:
-15.66%
6M Performance:
+203.64%
1Y Performance:
+145.23%
1-Day Range:
$33.20
$34.63
1-Week Range:
$33.20
$42.75
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
33.40 | 231.66M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor biopharma $3.5m stock sale by ten percent owner - Investing.com India
Can momentum traders help lift Vor Biopharma Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Applying sector rotation models to Vor Biopharma Inc.2025 Key Lessons & Consistent Growth Equity Picks - newser.com
Will Vor Biopharma Inc. bounce back from current support2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com
Relative strength of Vor Biopharma Inc. in sector analysisWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What’s the recovery path for long term holders of Vor Biopharma Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Tick level data insight on Vor Biopharma Inc. volatilityJuly 2025 Sector Moves & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 00:08:46 - newser.com
What analyst consensus says on Vor Biopharma Inc. stockBull Run & Reliable Volume Spike Trade Alerts - newser.com
Vor Bio Surges: Analysts See Bright Future - timothysykes.com
Published on: 2025-09-30 05:10:46 - newser.com
Vor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46 - Nasdaq
Vor Biopharma | EFFECT: Others - 富途牛牛
Vor Bio Announces Late-Breaking Poster Presentation of - GlobeNewswire
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025 - Yahoo Finance
What drives Vor Biopharma Inc stock priceInsider Trading Activity & Build Diversified Portfolios With Ease - earlytimes.in
Is Vor Biopharma Inc a good long term investmentTrendline Breakouts & Reinvest for Maximum Compounding Returns - Early Times
What analysts say about Vor Biopharma Inc stockMarket Liquidity Analysis & AI-Based Predictions Available Free - earlytimes.in
Published on: 2025-09-27 19:29:37 - newser.com
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha
Vor Biopharma Shares Slide Following Warrant Registration Filing - MSN
Vor Biopharma stock drops after filing to register warrant shares By Investing.com - Investing.com South Africa
Vor Biopharma stock drops after filing to register warrant shares - Investing.com
Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects By Investing.com - Investing.com South Africa
Vor Biopharma (VOR) Registers 51M Shares for Resale, Warrants in Focus - GuruFocus
Vor Biopharma files for offering of up to 51 million common shares by the selling stockholdersSEC filing - MarketScreener
Vor Biopharma (VOR) files for 51M share offering by selling stockholders - StreetInsider
Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects - Seeking Alpha
Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects - Investing.com India
Stifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to Buy - MarketBeat
Vor Biopharma climbs after Stifel upgrades rating on autoimmune drug potential - TradingView
Vor Biopharma (NYSE:VOR) Stock Price Down 8.6% Following Insider Selling - MarketBeat
Stifel Upgrades Vor Biopharma(VOR.US) to Buy Rating, Raises Target Price to $55 - 富途牛牛
Vor Biopharma’s Strategic Moves and Telitacicept’s Potential Drive Buy Rating Amid Stock Decline - TipRanks
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer - GlobeNewswire
Vor Bio appoints Navid Khan as chief medical affairs officer By Investing.com - Investing.com South Africa
Vor Bio appoints Navid Khan as chief medical affairs officer - Investing.com
Vor Biopharma (VOR) Sees Significant Increase in Borrow Rate - GuruFocus
7 Successful Drug Launches: Vor Bio Taps VYVGART Launch Veteran Navid Khan as Medical Affairs Chief - Stock Titan
Vor Biopharma (NASDAQ:VOR) Shares Down 7.2%What's Next? - MarketBeat
Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 22,363 Shares - MarketBeat
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reprogrammed Interchange LLC | 10% Owner |
Oct 03 '25 |
Sale |
37.83 |
7,901 |
298,911 |
1,597,308 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 01 '25 |
Sale |
39.19 |
1,400 |
54,870 |
1,637,660 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 16 '25 |
Sale |
1.54 |
447,278 |
688,853 |
32,781,209 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 15 '25 |
Sale |
1.64 |
400,000 |
656,320 |
33,228,487 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 12 '25 |
Sale |
1.75 |
300,000 |
526,230 |
33,628,487 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 11 '25 |
Sale |
1.83 |
284,805 |
521,421 |
33,928,487 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 08 '25 |
Sale |
1.99 |
464,421 |
924,058 |
35,012,518 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 09 '25 |
Sale |
2.00 |
449,226 |
898,632 |
34,563,292 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 10 '25 |
Sale |
1.82 |
350,000 |
635,285 |
34,213,292 |
| Reprogrammed Interchange LLC | 10% Owner |
Sep 03 '25 |
Sale |
2.00 |
554,612 |
1,107,061 |
36,329,955 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):